Comparative Pharmacology
Head-to-head clinical analysis: ACARBOSE versus MIGLITOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACARBOSE versus MIGLITOL.
ACARBOSE vs MIGLITOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acarbose is a complex oligosaccharide that competitively and reversibly inhibits α-glucosidase enzymes in the brush border of the small intestine. This delays the digestion and absorption of complex carbohydrates and disaccharides, thereby reducing postprandial hyperglycemia.
Reversible competitive inhibitor of alpha-glucosidase in the intestinal brush border; delays glucose absorption and lowers postprandial hyperglycemia.
Initial: 25 mg orally 3 times daily with first bite of each main meal; maintenance: 50-100 mg 3 times daily; max 100 mg 3 times daily.
25 mg orally three times daily with the first bite of each main meal; may increase to 50 mg three times daily after 4-8 weeks, maximum 100 mg three times daily.
None Documented
None Documented
Clinical Note
moderateAcarbose + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Acarbose."
Clinical Note
moderateAcarbose + Gatifloxacin
"Acarbose may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateMiglitol + Gatifloxacin
"Miglitol may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateAcarbose + Rosoxacin
"Acarbose may increase the hypoglycemic activities of Rosoxacin."
Terminal elimination half-life is approximately 2.5 to 3 hours for the parent compound, but the drug acts locally in the GI tract; systemic half-life is not clinically relevant for its pharmacodynamic effect.
Plasma elimination half-life ≈ 2 hours; clinical effect (alpha-glucosidase inhibition) persists longer due to enzyme binding; half-life increases in renal impairment (creatinine clearance < 25 mL/min).
Primarily excreted unchanged in feces (approximately 50% of an oral dose) and as metabolites via the gastrointestinal tract; less than 2% of the dose is recovered in urine as active drug or metabolites. Renal excretion is minimal.
Primarily excreted unchanged in urine (≈ 65%) via glomerular filtration; remainder recovered as metabolites in urine (25%) and feces (5%); total recovery in urine and feces ≈ 95% within 24 hours.
Category C
Category A/B
Alpha-Glucosidase Inhibitor
Alpha-Glucosidase Inhibitor